A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: Planning, expectations and reality

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 376-381

  Labopin, M ^a   Gorin, N C ^a   Polge, E ^a   Socie G ^b   Gurman, G ^c   Gluckman, E ^b,d   Jindra, P ^e   Poire X ^f   Schafer Eckart K ^g   Ruutu, T ^h   Milone, G ⁱ   Arcese, W ^j   Mohty, M ^a   Rocha, V ^a,b,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CHARLES UNIVERSITY   (Czech Republic)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Medizinische Klinik   (Germany)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ Ospedale Ferrarotto   (Italy)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

acute leukemia; prospective registration study; stem cell transplantation

Indexed keywords

ANTILEUKEMIC AGENT; HLA ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; EXPECTATION; FEASIBILITY STUDY; FEMALE; HLA TYPING; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PATIENT SCHEDULING; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; REGISTRATION; SIBLING; TREATMENT PLANNING; UNRELATED DONORS; YOUNG ADULT; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REGISTER; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROBABILITY; PROSPECTIVE STUDIES; REGISTRIES; REMISSION INDUCTION; SIBLINGS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904242613     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.178     Document Type: Article

References (19)

1. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923.
2. Gratwohl A. Cord blood meets its match. Lancet Oncol 2011; 12: 1177-1178.
3. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485-501.
4. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
5. Gratwohl A, Baldomero H. European survey on clinical use of cord blood for hematopoietic and non-hematopoietic indications. Transfus Apher Sci 2010; 42: 265-275.
6. Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118: 6037-6042.
7. Suciu S. on behalf of the AMLcgoE. Metaanalysis of randomised trials comparing autologous BMT (ABMT) vs chemotherapy (CT) or ABMT vs no further treatment (NFT) as post remission treatment in adult AML patients. Bone Marrow Transplant 1998; 21: 43a.
8. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M, Juliusson G et al. The European LeukemiaNet AML Working Party consensus statement on allo-geneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9: 579-590.
9. Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T et al. The European LeukemiaNet: achievements and perspectives. Haematologica 2011; 96: 156-162.
10. Fine JPG, R.J. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
11. Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L et al. Impact of donor specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation. A Eurocord, Societe Francophone d'Histocompatibilite et d'Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica 2013; 98: 1154-1160.
12. Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013; 121: 752-758.
13. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclopho-sphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120: 4285-4291.
14. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-or high-risk acute mye-loid leukemia in first complete remission. Blood 2012; 119: 5584-5590.
15. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
16. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978-2986.
17. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Auto-logous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
18. Giebel S, Labopin M, Ehninger G, Beelen D, Blaise D, Ganser A et al. Association of human development index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood 2010; 116: 122-128.
19. Velardi A. Haplo-BMT: which approach? Blood 2013; 121: 719-720.